News
🇺🇸 AmericasLatest pharmaceutical news, drug approvals, and FDA regulatory updates
Breaking Medicus Pharma Ltd. to Present at Biotech Showcase 2026, Advancing SkinJect Program
Medicus Pharma Ltd. is set to present at Biotech Showcase 2026, highlighting the upcoming readout of its Phase 2 SkinJect clinical data. This presentation underscores the company's strategic focus on advancing select programs through proof-of-concept and pursuing strategic partnerships.
Latest News
Triple Hormone-Receptor Agonist Retatrutide for Obesity: Phase 3 Results and Market Impact
Eli Lilly's retatrutide, a triple hormone-receptor agonist, achieved up to 28.3% average weight loss in the Phase 3 TRIUMPH-1 trial. This article provides a competitive benchmarking analysis for pharma strategists and BD teams.
Exclusive: FDA issues industry-friendly gene therapy guidance: What BD teams need to know
The FDA issued draft guidance to help developers bring gene therapies to market more efficiently. This article explains the changes, their impact on pharma strategy, and what to watch next.
Johnson And Johnson ASCO 2026 Data Adds Depth To JNJ Valuation Story
Johnson & Johnson's ASCO 2026 data reinforces pipeline depth in oncology and autoimmunity, supporting a P/E of 26.6 and analyst target of US$252.87. Key readouts and competitive implications for B2B teams.
Pfizer's Berobenatide Obesity Drug: VESPER-3 Data and Competitive Outlook
Pfizer's monthly GLP-1 RA berobenatide (acquired from Metsera) shows continued weight loss in VESPER-3 Phase 2b data. This analysis covers efficacy, safety, and strategic implications for pharma teams.
Puma Biotechnology Inducement Awards: Strategic Talent Moves Under Nasdaq Rule 5635(c)(4)
Puma Biotechnology granted inducement awards to new employees under Nasdaq Listing Rule 5635(c)(4) on June 3, 2026. The move signals strategic talent acquisition and potential pipeline focus.
Facet Life Sciences Appoints Frank Closurdo as VP, Commercial Services
Facet Life Sciences has appointed Frank A. Closurdo as Vice President of Commercial Services, a move that deepens the firm's ability to combine regulatory strategy with market access guidance. The appointment signals Facet's continued expansion into integrated advisory services for life science companies.
Pfizer's Berobenatide: Monthly Obesity Drug Shows Promise in Phase 2b
New Phase 2b data for Pfizer's berobenatide (formerly MET097) show robust and continuous weight loss with monthly dosing, reinforcing its potential as a differentiated obesity therapy. The results offer key insights for analysts and BD teams tracking the Pfizer weight loss drug name and the broader obesity pipeline.
Listeria Outbreak in Soft Cheese: FDA Investigation and Industry Impact
The FDA and CDC are investigating a multi-state, multi-year Listeria monocytogenes outbreak linked to requeson soft cheese, with eight cases and one death. This article outlines the development, regulatory actions, and implications for pharmaceutical and food safety teams.
CDC: Ebola outbreak in Central Africa could reach 20,000 cases without strong countermeasures
A new CDC analysis warns the Ebola outbreak in Central Africa could reach 20,000 cases without strong countermeasures. This article examines the modeling, current case counts, and implications for pharma teams.
FDA Issues June 2026 Guidance: Gene Therapy, Payor Comms, and CMC Flexibilities
The FDA released eight new guidance documents between April and June 2026, including draft guidances on gene therapy genome editing and payor communications, plus final guidances on pregnancy safety studies and CMC flexibilities for cell and gene therapies. These updates signal the agency's evolving regulatory approach and create both opportunities and compliance requirements for pharmaceutical companies.
Friday Five: ASCO Takeaways, ADA Focus, China Deals & More – Clinical Trials
This week's Friday Five covers standout data from ASCO 2025, including Revolution Medicines' pancreatic cancer results, a preview of the upcoming ADA meeting, and a significant Eli Lilly deal in China. The roundup also highlights ADC safety findings and a new BMS-Hengrui collaboration, providing decision-useful insights for pharma stakeholders.
Pharmalittle: Roche accuses U.S. of 'blackmail,' Supreme Court rules on skinny labels
Roche's chairman calls U.S. drug pricing policy 'blackmail,' while the Supreme Court issues a ruling on skinny labels. This article breaks down what changed, who is affected, and what to watch next.
Ebola 2026: US Response and Travel Restrictions Debate
The 2026 Ebola outbreak has reignited debate over US travel restrictions and the right of American healthcare workers to return home. This article examines the policy, public health, and industry implications.
Senior NIH official pushes MAHA strategy to skeptical ADA audience
Senior NIH official Richard Woychik presented the MAHA strategy to a skeptical ADA audience in New Orleans, emphasizing alignment with NIH priorities. The event highlights growing tension between public health research and political agendas.
STAT+: Newer GLP-1s, pushback on research cuts, and a protest
At the ADA conference, newer GLP-1s were highlighted alongside growing pushback against research funding cuts and a related protest. This article analyzes the developments and their impact on pharma strategy.
Abivax colitis drug hits goal, but cancer cases rattle investors
Abivax's obefazimod met primary efficacy endpoints in a late-stage ulcerative colitis trial, but three cancer cases among treated patients sent shares down 27%. The safety signal, deemed unrelated by investigators, creates uncertainty for regulatory filings and partnership discussions.
Supreme Court sides with generic drug maker in icosapent ethyl patent case
The U.S. Supreme Court unanimously sided with generic drug maker Hikma Pharmaceuticals in a patent case brought by Amarin Pharma over icosapent ethyl. The decision clears the way for Hikma's sale of the generic version in the U.S. market.
Rx Rundown: Pfizer, Hikma Pharmaceuticals, NewLimit — Drug Approvals & Catalyst Tracker
Pfizer, Hikma Pharmaceuticals, and NewLimit are at the center of recent FDA actions. This rundown covers approvals, withdrawals, and upcoming catalysts for pharma BD and investors.
MIRA Pharma Consolidates Global Rights to MIRA-55 and SKNY-1
MIRA Pharmaceuticals amends its MIRALOGX license to secure worldwide exclusive development and commercialization rights for MIRA-55 and SKNY-1, without altering core economics. The move strengthens IP control and follows peer-reviewed data on SKNY-1's obesity and nicotine addiction potential.
4 Biotech Stocks Investors Should Watch in 2026: Market Analysis
This article highlights four biotech stocks—Argenx, BeOne Medicines, IQVIA, and BioNTech—with implied upside ranging from 28% to 41% in 2026. It provides catalyst-driven analysis for investors and pharma BD teams.